IRIS
GALETTI, Maricla
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.225
NA - Nord America 2.997
AS - Asia 1.599
SA - Sud America 289
AF - Africa 62
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 8.177
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.951
IT - Italia 907
CN - Cina 771
SG - Singapore 568
FI - Finlandia 544
IE - Irlanda 489
SE - Svezia 423
BR - Brasile 262
DE - Germania 248
UA - Ucraina 133
NL - Olanda 119
TR - Turchia 88
FR - Francia 74
IN - India 70
RU - Federazione Russa 64
GB - Regno Unito 61
AT - Austria 50
CI - Costa d'Avorio 48
BE - Belgio 40
CA - Canada 34
ID - Indonesia 18
HK - Hong Kong 14
AR - Argentina 12
CZ - Repubblica Ceca 12
ES - Italia 12
VN - Vietnam 11
MX - Messico 9
PL - Polonia 8
EC - Ecuador 7
PK - Pakistan 7
BD - Bangladesh 6
CH - Svizzera 6
IR - Iran 6
LT - Lituania 6
HU - Ungheria 5
UZ - Uzbekistan 5
IQ - Iraq 4
JO - Giordania 4
KG - Kirghizistan 4
PS - Palestinian Territory 4
AL - Albania 3
AZ - Azerbaigian 3
KE - Kenya 3
NO - Norvegia 3
NP - Nepal 3
NZ - Nuova Zelanda 3
PT - Portogallo 3
RO - Romania 3
ZA - Sudafrica 3
CO - Colombia 2
CY - Cipro 2
EE - Estonia 2
EG - Egitto 2
GR - Grecia 2
JP - Giappone 2
LB - Libano 2
MA - Marocco 2
PA - Panama 2
PY - Paraguay 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
TJ - Tagikistan 2
VE - Venezuela 2
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EU - Europa 1
GA - Gabon 1
KR - Corea 1
KZ - Kazakistan 1
LU - Lussemburgo 1
LV - Lettonia 1
MY - Malesia 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 8.177
Salva come PNG Salva come JPEG
Città #
Dublin 489
Chandler 474
Parma 329
Singapore 307
Santa Clara 305
Ann Arbor 273
Ashburn 167
Jacksonville 158
Beijing 153
Dearborn 153
Boardman 137
Shanghai 115
Nanjing 97
Princeton 74
Izmir 72
New York 66
Chicago 64
Milan 61
Bremen 57
San Mateo 51
Abidjan 48
Helsinki 47
Wilmington 47
Vienna 44
Munich 40
Shenyang 39
Moscow 38
Nanchang 35
Los Angeles 32
Kunming 30
Des Moines 28
Marseille 28
Hefei 27
Modena 27
Jinan 26
Rome 25
São Paulo 25
Bologna 24
Brussels 23
Seattle 22
The Dalles 22
Tianjin 22
Hebei 21
Toronto 20
Turku 19
Jakarta 18
Reggio Emilia 16
Council Bluffs 15
London 15
Nuremberg 15
Redmond 15
Columbus 14
Dallas 14
Frankfurt am Main 14
Hong Kong 14
Jiaxing 14
Changsha 13
Norwalk 13
Pune 13
Verona 13
Amsterdam 12
Brasília 12
Düsseldorf 12
Houston 12
Leawood 12
Wayne 12
Woodbridge 12
Guangzhou 11
Zhengzhou 11
Dong Ket 10
Augusta 8
Bari 8
Bengaluru 8
Fremont 8
Manchester 8
Ningbo 8
Rio de Janeiro 8
Binche 7
Florence 7
Genoa 7
Haikou 7
Neviano degli Arduini 7
Redwood City 7
Belo Horizonte 6
Brno 6
Castello Molina di Fiemme 6
Falls Church 6
Fuzhou 6
Hangzhou 6
Leuven 6
Monmouth Junction 6
Montecchio Emilia 6
Montreal 6
Ottawa 6
Phoenix 6
Piacenza 6
Salsomaggiore Terme 6
Taiyuan 6
Wuhan 6
Brescia 5
Totale 4.892
Salva come PNG Salva come JPEG
Nome #
Highly-defined bioprinting of long-term vascularized scaffolds with Bio-Trap: Complex geometry functionalization and process parameters with computer aided tissue engineering 170
A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC 169
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 158
Subchronic exposure to titanium dioxide nanoparticles modifies cardiac structure and performance in spontaneously hypertensive rats 157
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 147
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 137
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 135
Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line 131
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 127
Nanoparticles exposure: In-vitro and in-vivo investigation to evaluate cardiovascu1ar risk factors in normal and failing cardiac tissue [Esposizione a nanoparticelle: Studi in-vitro ed in-vivo per valutare i fattori di rischio cardiovascolari in cuori normali e patologici] 123
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 122
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 120
Autophagy and apoptosis: studies on the effects of bisthiosemicarbazone copper(II) complexes on p53 and p53-null tumour cell lines 119
Synthesis of Fe3O4 superparamagnetic nanoparticles and anchoring via ‘click’ chemistry to SiC/SiO2 nanowires for radiofrequency magnetic field hyperthermia 117
Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumab 117
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 115
Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung 113
Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method 112
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line 112
Titanium dioxide aggregating nanoparticles induce autophagy and under-expression of microRNA 21 and 30a in A549 cell line: A comparative study with cobalt(II, III) oxide nanoparticles 111
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 111
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 110
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 109
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 109
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 108
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 108
New MDR1 inhibitors for overcoming multidrug resistance 108
Sirolimus plus prednisone for Erdheim-Chester disease: An open-label trial 107
Cytocompatibility and Cellular Internalization Mechanisms of SiC/SiO2 Nanowires 107
A three-fold novel nanosystem made by SiC/SiO2 core/shell nanowires functionalized with magnetic nanoparticles and substituted porphyrin for nanomedicine applications 107
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 103
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 102
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 101
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 101
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 101
SiC/SiO2/M-NP core/shell nanowires functionalized with fluorinated porphyrins 101
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 98
Three-Dimensional Bioprinting of Organoid-Based Scaffolds (OBST) for Long-Term Nanoparticle Toxicology Investigation 96
Gefitinib metabolism by CYP1A1 affects biological responses in NSCLC cell lines. 95
CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms 95
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 94
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) 93
Anti-proliferative and pro-apoptotic effects of Sorafenib in breast cancer cells in vitro. 93
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 92
Coordinated inducible expression of p53 and FHIT has a strong anti proliferative effect in Calu-1 lung cancer cell line. 92
5-benzylidene-hydantoin UPR 1024 acts as EGFR inhibitor and induces DNA damage in A549 NSCLC cell line 92
SiO2/SiC core-shell nanowires for nanomedicine applications 92
Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line 91
New strategies to overcome resistance to EGFR tyrosine kinase inhibitors in non small cell lung cancer 90
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 89
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells 89
Cytocompatible 3C-SiC/SiO2 core shell nanowires for bimodal cancer therapy 88
Synergistic activity of letrozole and sorafenib on MCF7/AROM-1 breast cancer cells 88
CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS 87
Association of serum C3 concentration and histologic signs of thrombotic microangiopathy with outcomes among patients with ANCA-associated renal vasculitis 87
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 84
Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling 83
SiO2/SiC core-shell nanowires for nanomedicine applications 82
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 80
Glomerular autoimmune multicomponents of human lupus nephritis in vivo: α-enolase and annexin AI 80
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines 80
Effect of constitutive or inducible expression of the FHIT gene in a lung cancer cell line 80
Cardiac kinematic parameters computed from video of in situ beating heart 80
A Photoactive Supramolecular Complex Targeting PD-L1 Reveals a Weak Correlation between Photoactivation Efficiency and Receptor Expression Levels in Non-Small-Cell Lung Cancer Tumor Models 79
Study and characterization of a new magnetic nanocomposite system for nanomedicine 78
Modulazione della riespressione del gene FHIT in cellule di carcinoma polmonare 77
Epidermal Growth Factor Receptor Intron-1 Polymorphism Predicts Gefitinib Outcome in Advanced Non-small Cell Lung Cancer 74
Role of cell gefitinib metabolism in the response of NSCLC cell lines to gefitinib. 73
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones 73
Anti-proliferative effect of induced Fhit expression in non small cell lung cancer cell line (Calu-1) 69
The inducible coexpression of p53 and FHIT has a synergistic anti-proliferative effect in calu-1 lung cancer cell line 67
The maintenance of gefitinib inhibits migration and epithelial-mesenchimal transition of Non-small cell lung cancer cell lines that have become resistant after prolonged gefitinib treatment 67
Glomerular autoimmune multicomponents of human lupus nephritis in vivo (2): Planted antigens 65
Optimizing EGFR inhibitor treatment in non small cell lung cancer 64
Synergistic activity of letrozole and sorafenib on breast cancer cells 64
Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines 64
Espressione Inducibile del gene FHIT in cellule di carcinoma polmonare 62
T-DM1: a new therapeutic approach in HER-2 overexpressing NSCLC cell lines 61
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 61
Effect of inducile FHIT and p53 expression in Calu-1 lung cancer cell line. 60
Studio dell’espressione del gene FHIT in cellule di carcinoma polmonare 59
New irreversible inhibitors of EGFR tyrosine kinase activity to circumvent iressa resistance 57
Interaction between occupational radon exposure and tobacco smoke: a systematic review 55
Interaction between Occupational and Non-Occupational Arsenic Exposure and Tobacco Smoke on Lung Cancerogenesis: A Systematic Review 53
In vitro characterization of efflux and metabolism of gefitinib 51
Espressione inducibile di Fhit e p53 in cellule di carcinoma polmonare non a piccole cellule 49
Chapter 9 - Innovation in nanomedicine and engineered nanomaterials for therapeutic purposes 46
Critical Issues in Assessing Occupational Exposure to Diesel Dust Exhaust 33
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells (Frontiers in Oncology, (2022), 12, (942341), 10.3389/fonc.2022.942341) 32
null 31
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators 29
Effect of inducible Fhit and p53 expression in Calu-1 lung cancer cell line 24
Totale 8.372
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.633
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.633
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202092 0 0 0 0 0 0 0 0 0 0 40 52
2020/2021569 9 48 37 34 54 26 46 44 106 23 101 41
2021/2022427 30 19 22 29 15 9 56 36 23 24 24 140
2022/20231.873 151 225 122 118 172 208 18 138 599 17 78 27
2023/2024981 44 77 49 37 68 175 78 91 39 59 105 159
2024/20252.321 128 128 163 206 251 312 184 134 351 222 242 0
Totale 8.372